Abnormal prorenin processing in growth hormone deficiency. 2005

Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. msgordon@bics.bwh.harvard.edu

Growth hormone deficiency (GHD) is associated with increased premature cardiovascular (CV) mortality. Abnormal cardiac structure and function, including autonomic adrenergic dysfunction as detected by heart rate variability analysis, have been described in GHD. Abnormal prorenin processing resulting in a reduced renin/prorenin ratio has been correlated with cardiac autonomic dysfunction, an established risk factor for CV mortality, in diabetic patients. We investigated renin/prorenin ratios in untreated GHD patients (n=31) and in a group of GHD patients treated with GH (n=23) and compared both groups to a group of 59 normal control subjects. The treated GHD group was replaced with GH for a mean duration of 49.4+/-6.7 months. The mean renin/prorenin ratios were 0.0765+/-0.0089 in the untreated GHD group, 0.113+/-0.018 in the treated GHD group, and 0.304+/-0.029 in the control group (P<0.01, untreated GHD or treated GHD vs. normal controls; P=NS, untreated GHD vs. treated GHD). These results demonstrate that GHD is characterized by abnormal prorenin processing implicating concomitant cardiac autonomic adrenergic dysfunction, a risk factor for increased CV mortality. GH treatment resulted in a non-significant trend towards normalizing this defect.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D046188 Protein Modification, Translational Any of the enzymatically catalyzed modifications of the individual AMINO ACIDS of PROTEINS, and enzymatic cleavage or crosslinking of peptide chains that occur pre-translationally (on the amino acid component of AMINO ACYL TRNA), co-translationally (during the process of GENETIC TRANSLATION), or after translation is completed (POST-TRANSLATIONAL PROTEIN PROCESSING). Amino Acid Modification, Co-Translational,Protein Modification, Co-Translational,Protein Processing, Co-Translational,Protein Processing, Translational,Amino Acid Modification, Pre-Translational,Amino Acid Modification, Pretranslational,Amino Acid Modification, Translational,Co-Translational Amino Acid Modification,Co-Translational Protein Modification,Co-Translational Protein Processing,Cotranslational Protein Modification,Cotranslational Protein Processing,Pre-Translational Amino Acid Modification,Pretranslational Amino Acid Modification,Translational Amino Acid Modification,Translational Protein Modification,Translational Protein Processing,Amino Acid Modification, Co Translational,Amino Acid Modification, Pre Translational,Co Translational Amino Acid Modification,Co Translational Protein Processing,Co-Translational Protein Modifications,Cotranslational Protein Modifications,Modification, Co-Translational Protein,Modifications, Co-Translational Protein,Pre Translational Amino Acid Modification,Processing, Co-Translational Protein,Protein Modification, Co Translational,Protein Modification, Cotranslational,Protein Modifications, Co-Translational,Protein Modifications, Cotranslational,Protein Modifications, Translational,Protein Processing, Co Translational,Protein Processing, Cotranslational,Translational Protein Modifications

Related Publications

Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
January 2001, Circulation,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
February 2000, The Journal of clinical endocrinology and metabolism,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
July 2002, BMJ (Clinical research ed.),
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
January 2016, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
September 2020, EMBO molecular medicine,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
March 2014, EMBO molecular medicine,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
January 1999, Hormone research,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
September 1967, Lancet (London, England),
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
May 2006, Nihon rinsho. Japanese journal of clinical medicine,
Michael S Gordon, and Anne L Caston-Balderrama, and Murray B Gordon
September 1987, Annals of clinical biochemistry,
Copied contents to your clipboard!